26 of 28 included studies were sponsored by Merck or GSK, representing 99.6% of the weighted data. Authors use on-drug trial data as a proxy for a post-drug syndrome—a fatal flaw.
This post responds to a recent research letter: Disproportional signal of sexual dysfunction reports associated with finasteride use in young men with androgenetic alopecia: a pharmacovigilance analysis of VigiBase.
A thread originally posted on Twitter is reproduced below. For an in-depth version, see the essay Context matters. See also a critique of three previous papers with similar designs, findings and conclusions. Twitter thread Nguyen et al, 2022 is the fourth analysis of adverse events of finasteride to appear since 2018. All four studies play … Read more
Although finasteride came on the market in the 1990s, the science that led to its development began two decades earlier. The rationale for the drug emerged from a study of a unique group of people in a remote village in the Dominican Republic called Las Salinas. Locals there have long known about children who follow … Read more
A 2018 article disclosed that Dr. Kevin McVary had been retained as an expert for Merck’s defense in litigation regarding persistent adverse effects (AEs) of finasteride.1 Dr. McVary has also been relatively active as a contributor of three conference abstracts, an original article, an expert review, a quote in a media story and a symposium presentation … Read more
A fourth study has been published in the ‘literature of doubt’. Read the rebuttal. Background on the co-author of Baas et al, 2018 with a disclosed conflict of interest is here. Three studies analyzing adverse event (AE) data related to finasteride and dutasteride were published from 2018–2020 (the “AE papers”).1–3 The first to appear, by Baas … Read more
Men who previously took finasteride and dutasteride have reported sexual dysfunction, anxiety, depression, cognitive problems and other dysfunctions which have continued long after stopping the drug. This paper proposes an explanation for how these dysfunctions may develop.
Simple summary: Numerous studies have shown that treatment with finasteride and dutasteride can change the size, tissue composition and function of the prostate and penis. Changes in the penis linked to finasteride or dutasteride treatment include: reduced size and weight; reduced erectile response; decreased smooth muscle; increased collagen density; fibrosis (scarring or other tissue abnormalities); … Read more
Summary This post documents adverse events (AEs) of finasteride affecting male reproductive anatomy and sexual function in men age 18–40, reported to US FDA from 2000 to 2020. See the Methodology section for more details. Categories in the table are not in the source data, but were applied based on AE descriptions: Category Adverse events(2000–2020) … Read more
Most-published researchers This post covers researchers who have published at least three papers on adverse effects of finasteride and 5-alpha reductase inhibitors when taken as a treatment for hair loss, typically by younger men. Collectively, this group has published more than 60 papers on this topic. Keep in mind these caveats: This list does not … Read more